Champions Oncology, Inc.

🚨 Now Enrolling: Systemic AML In Vivo Screen – Until May 15th, 2025! 🚨 Champion’s Systemic Acute-Myeloid Leukemia AML In Vivo Screen features 27 rare, patient-derived AML models, meticulously characterized to retain key AML-specific molecular characteristics and mutations. These extensively characterized models provide a clinically relevant platform to evaluate therapeutic efficacy, with several models pretreated using advanced therapies like FLT3 inhibitors, anti-CD33 ADCs, and stem cell transplants—helping researchers accelerate the next generation of AML therapeutics. 📅 Secure your spot today. Let’s accelerate AML breakthroughs together: https://hubs.li/Q03b26jG0 #AMLResearch #Hematology #DrugDiscovery #OncologyResearch #PreclinicalModels #DrugDevelopment #PreclinicalStudies #AcuteMyeloidLeukemia #invivo #bloodcancers

⏳ Only 3 days left! Have you secured your spot? ⏳ Don’t miss your chance to attend Champions Oncology’s Annual European Translational Oncology Symposium on March 13th, 2025, in Basel—a complimentary event featuring leading experts. This event will bring together top experts from Roche, IGI (Ichnos Glenmark Innovation), Debiopharm FoRx Therapeutics, and more to share insights on the latest preclinical IO & oncology breakthroughs. Don’t miss this chance to network, gain knowledge, and help shape the future of oncology drug development. 📍 Hotel Victoria, Basel 📅 Thursday, March 13, 2025 | 8:30 AM - 4:00 PM 🔗 Only limited seats available—register now : https://hubs.li/Q03b25d20 #CancerResearch #OncologySymposium #MedicalBreakthroughs #ImmunoOncology #PreclinicalResearch

📢 Are you attending the 19th WRIB (April 7-11, 2025) in New Orleans? Visit us at Booth #1 to meet our experts, Chelsea Riveley, MBA, Jackie Naik, and Troy Tremaine, MBA, and learn more about our global clinical specialty testing services. From GCLP-compliant service platforms and custom assay development to high-complexity bioanalytical insights, Champions delivers the highest quality, custom solutions for your clinical trials. Stop by Booth #1 or schedule a meeting with our team: https://hubs.li/Q039Y2QZ0 #WRIB2025 #ClinicalTrials #Biomarkers #AssayDevelopment #ClinicalTesting #cancerresearch #flowcytometry

We’re happy to welcome Stefano Cairo, PhD, Sr. Global Scientific Director at Champions Oncology, as a distinguished speaker at our Annual European Translational Oncology Symposium on March 13th in Basel, Switzerland. Dr. Cairo, a molecular biologist with deep expertise in translational oncology research, leads multiple research initiatives at Champions. In his talk, “Powering Preclinical Breakthroughs with Ex Vivo and In Vivo PDX Models,” Dr. Cairo will explore how Champions’ ex vivo and in vivo platforms are accelerating cancer drug development and translational research. 💡 Don’t miss this insightful session! 🎟️ Seats are complimentary but limited—secure yours today: https://hubs.li/Q039VTJs0 #OncologyInnovation #CancerResearch #TranslationalOncology2025 #CancerTherapies #ImmunoOncology #PreclinicalResearch #OncologySymposium #ADC #IO #Basel #switzerland #EU #EXVIVO #InVIVO

📝Our latest blog explores how immunohistochemistry (IHC) and next-generation sequencing (NGS) are revolutionizing ADC development. Antibody-drug conjugates (ADCs) are changing the landscape of cancer treatment, but predicting their effectiveness remains a challenge. Read our latest blog to learn how Immunohistochemistry (IHC) and Next-Generation Sequencing (NGS) are key to refining patient selection and improving treatment success. 💡 Stay ahead in ADC development—read the full blog here 👉 #Antibodydrugconjugates #ADC #immunohistochemistry #NextGenerationSequencing #CancerResearch #PrecisionMedicine #IHC #NGS #Oncology https://hubs.li/Q039Rr-n0

The success of your research depends on the methodic and accurate selection of the most relevant tumor models. Lumin Analytics eliminates the guesswork and gives you access to the most comprehensive model characterization data in the industry. Explore Champions’ patient-derived preclinical model characteristics: ☑️Clinical annotations ☑️Proprietary genomic and proteomic profiles ☑️Proprietary in vivo pharmacological profiles Make data-driven decisions with confidence and accelerate your oncology research programs. Explore here: https://hubs.li/Q0395Z6P0 #Lumin #modelselection #omics #genomics #proteomics #oncologyresearch #cancerresearch #clinicalannotations #oncology

🚀 Now Enrolling: Champions' KRASmut In Vivo Screen – The premier preclinical platform for KRAS-targeted drug evaluation is enrolling until April 30th, 2025. Featuring 60 validated KRAS PDX models from primary patient tumors across 11 distinct cancer types including ovarian, NSCLC, pancreatic, and sarcoma cancers, this platform ensures a robust assessment of therapeutic efficacy. With key KRAS mutations (G12C, G12D, G12R, G12V, G13D, and more) and prior exposure to next-generation treatments, these models offer unparalleled translational relevance. ✅Ready to take your KRAS-targeted pipeline to the next level? Enroll Today: https://hubs.li/Q0395_8B0 #KRAS #OncologyResearch #DrugDiscovery #CancerTherapeutics #RAS #invivo #drugscreening #PDX #KRASmutation #cancer

📢Planning to attend IO360 in Boston? Let's meet! 💡Our experts Mara Gilardi, PhD, Nathalie Leger, and Chelsea Riveley, MBA will be at booth #11, ready to discuss our vast portfolio of ex vivo & in vivo platforms to support preclinical drug development projects and a fully compliant suite of clinical specialty testing services to assist with successful clinical trials. Let’s connect! Book a meeting with us now: https://hubs.li/Q038-13H0 #IO360 #ClinicalResearch #DrugDevelopment #preclinicalresearch #immunooncology #immunotherapy #Oncology #cancerresearch

🧬 We’re thrilled to welcome Serena Bologna, PhD, Principal Scientist at FoRx Therapeutics, as a guest speaker at Champions’ Annual European Translational Oncology Symposium on March 13, 2025, in Basel, Switzerland! 🔬With over 15 years of expertise in cancer biology and DNA damage repair pathways, Dr. Bologna has contributed significantly to the discovery of novel drug targets and predictive biomarkers. Her talk, "FORX-428: A Novel, Potent PARG Inhibitor Demonstrating Strong Anti-Tumor Activity in Preclinical Cancer Models," will explore the exciting potential of PARG inhibition in cancer treatment. 📍Don’t miss this must-attend session : https://hubs.li/Q038ZV280 #OncologyInnovation #CancerResearch #TranslationalOncology2025 #CancerTherapies #ImmunoOncology #PreclinicalResearch #OncologySymposium #ADC #IO #Basel #switzerland #EU #colorectalcancer Swiss Biotech Association, BioAlps - Swiss Health Valley, Biopôle Lausanne

🚀 We are thrilled to announce that Prof. Enzo Medico, MD, PhD, from the University of Torino Medical School and Candiolo Cancer Institute will be joining us as a distinguished speaker at our Annual European Translational Oncology Symposium on March 13th in Basel, Switzerland! 🔬 Dr. Medico, a leading expert in translational cancer genomics, will present on: “Colorectal cancer precision medicine: from human tumors to preclinical models, and back”. His talk will explore how large collections of colorectal cancer (CRC) cell lines and patient-derived tumor xenografts (PDXs) are being leveraged for pharmacogenomic screening, drug repurposing strategies, and CAR-based adoptive immunotherapy. The symposium is complimentary but seats are limited | Register Today : https://lnkd.in/gddkzBUJ OncologyInnovation #CancerResearch #TranslationalOncology2025 #CancerTherapies #ImmunoOncology #PreclinicalResearch #OncologySymposium #ADC #IO #Basel #switzerland #EU #colorectalcancer Swiss Biotech Association, BioAlps - Swiss Health Valley, Biopôle Lausanne